The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Chemical phylogenetics of histone deacetylases
Open accessAbstract
The broad study of histone deacetylases in chemistry, biology and medicine relies on tool compounds to derive mechanistic insights. A phylogenetic analysis of Class I and II HDACs as targets of a comprehensive, structurally diverse panel of inhibitors revealed unexpected isoform selectivity even among compounds widely perceived as non-selective. The synthesis and study of a focused library of cinnamic hydroxamates allowed the identification of a first non-selective HDAC inhibitor. These data will guide a more informed use of HDAC inhibitors as chemical probes and therapeutic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They have also been demonstrated to possess greater isoform selectivity profiles, targeting specifically only the class I subgroup of HDACs (6-10, 26, 38, 39).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“but their selectivity profiles extended well beyond these isoforms as reported previously (12, 13, 26, 29, 30, 38).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [26]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This is consistent with previous reports postulating that an intramolecular hydrogen bond between the amine and carbonyl must be broken to permit successful zinc chelation, and a desolvation penalty is paid for this rearrangement to occur (1, 25-28, 34).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [26]
Experimental — accuracy not yet measuredIn the citing paper
“Class IIa enzymes (Lahm et al., 2007) as well as HDAC3 (Madsen and Olsen, 2012a), HDAC8 (Bradner et al., 2010), and HDAC11 (Inks et al., 2012) removed the physiologically non-relevant trifluoroacetamide (Ktfa).”
From Histone deacetylase 11 is an ε-N-Myristoyllysine hydrolase (2018) · cites this paper as Bradner et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform
Katoh, K. (2002) · Nucleic Acids Research · doi:10.1093/nar/gkf436 · Cited by 17,027
A Rapid Bootstrap Algorithm for the RAxML Web Servers
Stamatakis, A., Hoover, P., & Rougemont, J. (2008) · Systematic Biology · doi:10.1080/10635150802429642 · Cited by 7,028
MAFFT version 5: improvement in accuracy of multiple sequence alignment
Katoh, K., Kuma, K., Toh, H., & Miyata, T. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki198 · Cited by 5,063
Lysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Recent developments in the MAFFT multiple sequence alignment program
Katoh, K., & Toh, H. (2008) · Briefings in Bioinformatics · doi:10.1093/bib/bbn013 · Cited by 3,629
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1779 · Cited by 2,234
Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action
Tsankova, N. M., Berton, O., Renthal, W., Kumar, A., Neve, R. L., & Nestler, E. J. (2006) · Nature Neuroscience · doi:10.1038/nn1659 · Cited by 1,780
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
Histone acetyltransferase complexes: one size doesn't fit all
Lee, K. K. W., & Workman, J. L. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2145 · Cited by 1,091
Flagged first, then by citations
Cited by
Sorted by citations
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515
Self-citationNew and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Epigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327
HDACs and HDAC Inhibitors in Cancer Development and TherapyPreprint
Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,337
Targeting the cancer epigenome for therapy
Jones, P. A., Issa, J. J., & Baylin, S. B. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.93 · Cited by 1,153
Lysine glutarylation is a protein posttranslational modification regulated by SIRT5
Tan, M., Peng, C., Anderson, K. A., Chhoy, P., Xie, Z., Dai, L., Park, J., Chen, Y., Huang, H., Zhang, Y., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.03.014 · Cited by 844
“…substrates containing 7-amino-4-methylcoumarin (AMC) were evaluated: one series based on a simple a-N-acetylated lysine (Figure 4A) and one containing the tripeptide sequence, Ac-Leu-Gly-Lys(acyl), which is based on H4K12—a common substrate for deacylation (Bradner et al., 2010) (Figure S4A).”
BackgroundClass I histone deacetylases (HDAC1–3) are histone lysine delactylases
Moreno-Yruela, C., Zhang, D., Wei, W., Bæk, M., Liu, W., Gao, J., Danková, D., Nielsen, A. L., Bolding, J. E., Yang, L., et al. (2022) · Science Advances · doi:10.1126/sciadv.abi6696 · Cited by 841
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Ho, T. C. S., Chan, A. H. Y., & Ganesan, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00830 · Cited by 795
Tham, Y. K., Bernardo, B. C., Ooi, J. Y. Y., Weeks, K. L., & McMullen, J. R. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1477-x · Cited by 732
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
Grasso, C. S., Tang, Y., Truffaux, N., Berlow, N. E., Liu, L., Debily, M.-A., Quist, M. J., Davis, L. E., Huang, E. C., Woo, P. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3855 · Cited by 687
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
Bantscheff, M., Hopf, C., Savitski, M. M., Dittmann, A., Grandi, P., Michon, A.-M., Schlegl, J., Abraham, Y., Becher, I., Bergamini, G., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1759 · Cited by 659
Santo, L., Hideshima, T., Kung, A. L., Tseng, J.-C., Tamang, D., Yang, M., Jarpe, M., van Duzer, J. H., Mazitschek, R., Ogier, W. C., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387365 · Cited by 616
Self-citationHistone deacetylases as regulators of inflammation and immunity
Shakespear, M. R., Halili, M. A., Irvine, K. M., Fairlie, D. P., & Sweet, M. J. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.04.001 · Cited by 546
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Topper, M. J., Vaz, M., Chiappinelli, K. B., DeStefano Shields, C. E., Niknafs, N., Yen, R.-W. C., Wenzel, A., Hicks, J., Ballew, M., Stone, M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.022 · Cited by 537
Delcuve, G. P., Khan, D. H., & Davie, J. R. (2012) · Clinical Epigenetics · doi:10.1186/1868-7083-4-5 · Cited by 505
Epigenetic Therapies for Cancer
Bates, S. E. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1805035 · Cited by 503
Recent developments of HDAC inhibitors: Emerging indications and novel molecules
Bondarev, A. D., Attwood, M. M., Jonsson, J., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14889 · Cited by 451
Lauffer, B. E. L., Mintzer, R., Fong, R., Mukund, S., Tam, C., Zilberleyb, I., Flicke, B., Ritscher, A., Fedorowicz, G., Vallero, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.490706 · Cited by 429
“SAHA and TSA exhibited potencies against HDAC1 and HDAC2 comparable with C1 and C2, but their selectivity profiles extended well beyond these isoforms as reported previously (12, 13, 26, 29, 30, 38).”
BackgroundTargeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need To Succeed
Gryder, B. E., Sodji, Q. H., & Oyelere, A. K. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.3 · Cited by 404
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Wagner, J. M., Hackanson, B., Lübbert, M., & Jung, M. (2010) · Clinical Epigenetics · doi:10.1007/s13148-010-0012-4 · Cited by 338
Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group
Lobera, M., Madauss, K. P., Pohlhaus, D. T., Wright, Q. G., Trocha, M., Schmidt, D. R., Baloglu, E., Trump, R. P., Head, M. S., Hofmann, G. A., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1223 · Cited by 385
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair
Lee, J., Choy, M. L., Ngo, L., Foster, S. S., & Marks, P. (2010) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1008522107 · Cited by 359
Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics
McClure, J. J., Li, X., & Chou, C. J. (2018) · Advances in cancer research · doi:10.1016/bs.acr.2018.02.006 · Cited by 360
On the Promise of Photopharmacology Using Photoswitches: A Medicinal Chemist’s Perspective
Fuchter, M. J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00629 · Cited by 353
The bromodomain protein Brd4 insulates chromatin from DNA damage signalling
Floyd, S., Pacold, M. E., Huang, Q., Clarke, S. M., Lam, F. C., Cannell, I. G., Bryson, B. D., Rameseder, J., Lee, M. J., Blake, E. J., et al. (2013) · Nature · doi:10.1038/nature12147 · Cited by 338
Self-citationCook, C. N., Carlomagno, Y., Gendron, T. F., Dunmore, J. H., Scheffel, K., Stetler, C. T., Davis, M., Dickson, D. W., Jarpe, M. B., Deture, M. A., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt402 · Cited by 325
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
Grant, C. M., Rahman, F., Piekarz, R., Peer, C. J., Frye, R., Robey, R. W., Gardner, E. R., Figg, W. D., & Bates, S. E. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.88 · Cited by 295
Target engagement and drug residence time can be observed in living cells with BRET
Robers, M. B., Dart, M. L., Woodroofe, C. C., Zimprich, C., Kirkland, T. A., Machleidt, T., Kupcho, K. R., Levin, S., Hartnett, J. R., Zimmerman, K., et al. (2015) · Nature Communications · doi:10.1038/ncomms10091 · Cited by 281
Acetylation site specificities of lysine deacetylase inhibitors in human cells
Schölz, C., Weinert, B. T., Wagner, S., Beli, P., Miyake, Y., Qi, J., Jensen, L. J., Streicher, W. W., McCarthy, A. R., Westwood, N. J., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3130 · Cited by 273
Self-citationTargeting Metalloenzymes for Therapeutic Intervention
Chen, A. Y., Adamek, R. N., Dick, B. L., Credille, C. V., Morrison, C. N., & Cohen, S. M. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00201 · Cited by 284
Chronic Pain: Emerging Evidence for the Involvement of Epigenetics
Denk, F., & McMahon, S. B. (2012) · Neuron · doi:10.1016/j.neuron.2012.01.012 · Cited by 274
Rational Therapeutic Combinations with Histone Deacetylase Inhibitors for the Treatment of Cancer
Thurn, K. T., Thomas, S., Moore, A. P., & Münster, P. N. (2011) · Future Oncology · doi:10.2217/fon.11.2 · Cited by 251
Determining target engagement in living systems
Simon, G. M., Niphakis, M. J., & Cravatt, B. F. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1211 · Cited by 245
Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors
Kalin, J. H., Wu, M., Gómez, A. V., Song, Y., Das, J., Hayward, D., Adejola, N., Wu, M., Panova, I. P., Chung, H. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02242-4 · Cited by 239
Self-citationTherapeutic potential for HDAC inhibitors in the heart
McKinsey, T. A. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134712 · Cited by 230
HDAC Inhibitors in Acute Myeloid Leukemia
José‐Eneriz, E. S., Gimenez-Camino, N., Agirre, X., & Prósper, F. (2019) · Cancers · doi:10.3390/cancers11111794 · Cited by 224
Coiffier, B., Pro, B., Prince, H. M., Foss, F. M., Sokol, L., Greenwood, M. J., Caballero, D. M., Morschhauser, F., Wilhelm, M., Pinter‐Brown, L. C., et al. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-11 · Cited by 212
Bradner, J. E., Mak, R., Tanguturi, S. K., Mazitschek, R., Haggarty, S. J., Ross, K., Chang, C. Y., Bosco, J., West, N., Morse, E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006774107 · Cited by 211
Self-citationMarcaurelle, L. A., Comer, E., Dandapani, S., Duvall, J. R., Gerard, B., Kesavan, S., Lee, M. D., Liu, H., Lowe, J. T., Marié, J., et al. (2010) · Journal of the American Chemical Society · doi:10.1021/ja105119r · Cited by 211
Self-citationNamdar, M., Perez, G., Ngo, L., & Marks, P. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013754107 · Cited by 210
Histone deacetylase 10 structure and molecular function as a polyamine deacetylase
Hai, Y., Shinsky, S. A., Porter, N. J., & Christianson, D. W. (2017) · Nature Communications · doi:10.1038/ncomms15368 · Cited by 200
Multiple roles of class I HDACs in proliferation, differentiation, and development
Reichert, N., Choukrallah, M.-A., & Matthias, P. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0921-9 · Cited by 194
Development of the first small molecule histone deacetylase 6 (HDAC6) degraders
Yang, K., Song, Y., Xie, H., Wu, H., Wu, Y.-T., Leisten, E. D., & Tang, W. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.05.057 · Cited by 190
Pipalia, N. H., Cosner, C. C., Huang, A., Chatterjee, A., Bourbon, P., Farley, N., Helquist, P., Wiest, O., & Maxfield, F. R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014890108 · Cited by 180
Rettig, I., Koeneke, E., Trippel, F., Mueller, W. C., Burhenne, J., Kopp‐Schneider, A., Fabian, J., Schober, A., Fernekorn, U., von Deimling, A., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.24 · Cited by 184
How Chemoproteomics Can Enable Drug Discovery and Development
Moellering, R. E., & Cravatt, B. F. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.01.001 · Cited by 182
Cavasin, M. A., Demos‐Davies, K., Horn, T. R., Walker, L. A., Lemon, D. D., Birdsey, N., Weiser‐Evans, M. C. M., Harral, J. W., Irwin, D. C., Anwar, A., et al. (2012) · Circulation Research · doi:10.1161/circresaha.111.258426 · Cited by 175
Therapeutic targets for cardiac fibrosis: from old school to next-gen
Travers, J. G., Tharp, C. A., Rubino, M., & McKinsey, T. A. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148554 · Cited by 179
Marek, M., Kannan, S., Hauser, A.-T., Moraes Mourão, M., Caby, S., Cura, V., Stolfa, D. A., Schmidtkunz, K., Lancelot, J., Andrade, L., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003645 · Cited by 173
HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic pain
Denk, F., Huang, W. L., Sidders, B. S., Bithell, A., Crow, M., Grist, J., Sharma, S., Ziemek, D., Rice, A. S. C., Buckley, N. J., et al. (2013) · Pain · doi:10.1016/j.pain.2013.05.021 · Cited by 172
Jia, H., Pallos, J., Jacques, V., Lau, A., Tang, B., Cooper, A. C., Syed, A., Purcell, J. M., Chen, Y., Sharma, S., et al. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.01.016 · Cited by 173
Jochems, J., Boulden, J., Lee, B. G., Blendy, J. A., Jarpe, M. B., Mazitschek, R., van Duzer, J. H., Jones, S. S., & Berton, O. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.207 · Cited by 175
Self-citationRomidepsin: a novel histone deacetylase inhibitor for cancer
Bertino, E. M., & Otterson, G. A. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.594437 · Cited by 174
HDAC inhibitors and immunotherapy; a double edged sword?
Kroesen, M., Gielen, P. R., Brok, I. C., Armandari, I., Hoogerbrugge, P. M., & Adema, G. J. (2014) · Oncotarget · doi:10.18632/oncotarget.2289 · Cited by 168
CAR-T cell combination therapy: the next revolution in cancer treatment
Al-Haideri, M. T., Tondok, S. B., Safa, S. H., Maleki, A. H., Rostami, S. M., Jalil, A. T., Al-Gazally, M. E., Alsaikhan, F., Rizaev, J. A., Mohammad, T. A. M., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02778-6 · Cited by 177
Foxp3 Post-translational Modifications and Treg Suppressive Activity
Deng, G., Song, X., Fujimoto, S., Piccirillo, C. A., Nagai, Y., & Greene, M. I. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02486 · Cited by 171
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
Minami, J., Suzuki, R., Mazitschek, R., Gorgun, G., Ghosh, B., Cirstea, D., Hu, Y., Mimura, N., Ohguchi, H., Cottini, F., et al. (2014) · Leukemia · doi:10.1038/leu.2013.231 · Cited by 159
Self-citationGhosh, S. K., Perrine, S. P., Williams, R. M., & Faller, D. V. (2011) · Blood · doi:10.1182/blood-2011-06-362434 · Cited by 159
Ha, K., Fiskus, W. C., Choi, D. S., Bhaskara, S., Cerchietti, L. C. A., Devaraj, S. G. T., Shah, B., Sharma, S., Chang, J. C., Melnick, A. M., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2154 · Cited by 158
Bürli, R. W., Luckhurst, C. A., Aziz, O., Matthews, K. L., Yates, D., Lyons, K. A., Beconi, M., McAllister, G., Breccia, P., Stott, A. J., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4011884 · Cited by 153
Luo, X., Liu, Y., Kubicek, S., Myllyharju, J., Tumber, A., Ng, S. S., Che, K. H., Podoll, J. D., Heightman, T. D., Oppermann, U. C. T., et al. (2011) · Journal of the American Chemical Society · doi:10.1021/ja201597b · Cited by 153
Histone deacetylase 3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammation
Leus, N. G. J., Zwinderman, M. R. H., & Dekker, F. J. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.06.019 · Cited by 153
Histone deacetylase inhibitors in hematological malignancies and solid tumors
Chun, P. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0571-1 · Cited by 151
Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
Verza, F. A., Das, U., Fachin, A. L., Dimmock, J. R., & Marins, M. (2020) · Cancers · doi:10.3390/cancers12061664 · Cited by 149
Espallergues, J., Teegarden, S. L., Veerakumar, A., Boulden, J., Challis, C., Jochems, J., Chan, M., Petersen, T. L., Deneris, E. S., Matthias, P., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.5634-11.2012 · Cited by 151
Hideshima, T., Qi, J., Paranal, R. M., Tang, W., Greenberg, E. F., West, N. H., Colling, M. E., Estiu, G. L., Mazitschek, R., Perry, J. A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608067113 · Cited by 146
Self-citationChemical genomics reveals histone deacetylases are required for core regulatory transcription
Gryder, B. E., Wu, L., Woldemichael, G. M., Pomella, S., Quinn, T. R., Park, P. M. C., Cleveland, A. H., Stanton, B. Z., Song, Y., Rota, R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11046-7 · Cited by 146
Histone deacetylase 11 is an ε-N-Myristoyllysine hydrolase
Moreno-Yruela, C., Galleano, I., Madsen, A. S., & Olsen, C. A. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.04.007 · Cited by 149
Molecular basis of organ fibrosis: Potential therapeutic approaches
Ghosh, A. K., Quaggin, S. E., & Vaughan, D. E. (2013) · Experimental Biology and Medicine · doi:10.1177/1535370213489441 · Cited by 142
Development of a histone deacetylase 6 inhibitor and its biological effects
Lee, J.-H., Mahendran, A., Yao, Y., Ngo, L., Venta-Perez, G., Choy, M. L., Kim, N., Ham, W.-S., Breslow, R., & Marks, P. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313893110 · Cited by 141
Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models
Huang, P., Almeciga-Pinto, I., Jarpe, M. B., van Duzer, J. H., Mazitschek, R., Yang, M., Jones, S. S., & Quayle, S. N. (2016) · Oncotarget · doi:10.18632/oncotarget.13738 · Cited by 138
Self-citationA Proton-Shuttle Reaction Mechanism for Histone Deacetylase 8 and the Catalytic Role of Metal Ions
Wu, R., Wang, S., Zhou, N., Cao, Z., & Zhang, Y. (2010) · Journal of the American Chemical Society · doi:10.1021/ja103932d · Cited by 135
Romidepsin for the Treatment of Peripheral T-Cell Lymphoma
Iyer, S. P., & Foss, F. M. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0043 · Cited by 134
Horton, J. R., Engstrom, A., Zoeller, E. L., Liu, X., Shanks, J. R., Zhang, X., Johns, M. A., Vertino, P. M., Fu, H., & Cheng, X. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.698449 · Cited by 132
Development and Therapeutic Implications of Selective Histone Deacetylase 6 Inhibitors
Kalin, J. H., & Bergman, J. A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4001659 · Cited by 131
Madsen, A. S., & Olsen, C. A. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203754 · Cited by 122
Wang, Y., Stowe, R. L., Pinello, C. E., Tian, G., Madoux, F., Li, D., Zhao, L. Y., Li, J.-L., Wang, Y., Wang, Y., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.12.015 · Cited by 122
“Although cyclic peptides are more potent against the class I HDACs (Bradner et al., 2010), the sulfhydryl group of romidepsin is thought to chelate zinc with little specificity (Arrowsmith et al., 2012).”
Chromatin as an expansive canvas for chemical biology
Fierz, B., & Muir, T. W. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.938 · Cited by 125
Hanson, J. E., La, H., Plise, E., Chen, Y.-H., Ding, X., Hanania, T., Sabath, E. V., Alexandrov, V., Brunner, D., Leahy, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069964 · Cited by 121
Cherng, C., Lee, K.-C., Chien, C., Chou, K.-Y., Cheng, Y., Hsin, S.-T., Lee, S.-O., Shen, C., Tsai, R., & Wong, C. (2013) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2013.04.007 · Cited by 119
Chemical Genetics–Based Target Identification in Drug Discovery
Cong, F., Cheung, A. K., & Huang, S.-M. A. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134639 · Cited by 118
HDAC8 catalyzes the hydrolysis of long chain fatty acyl lysine
Aramsangtienchai, P., Spiegelman, N. A., He, B., Miller, S. P., Dai, L., Zhao, Y., & Lin, H. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00396 · Cited by 118
Strategies To Design Selective Histone Deacetylase Inhibitors
Melesina, J., Simoben, C. V., Praetorius, L., Bülbül, E. F., Robaa, D., & Sippl, W. (2021) · ChemMedChem · doi:10.1002/cmdc.202000934 · Cited by 118
LAceP: Lysine Acetylation Site Prediction Using Logistic Regression Classifiers
Hou, T., Zheng, G., Zhang, P., Jia, J., Li, J., Xie, L., Wei, C., & Li, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089575 · Cited by 119
Konstantinopoulos, P. A., Wilson, A. J., Saskowski, J. L., Wass, E., & Khabele, D. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.03.007 · Cited by 115
Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension
Lemon, D. D., Horn, T. R., Cavasin, M. A., Jeong, M. Y., Haubold, K. W., Long, C. S., Irwin, D. C., McCune, S. A., Chung, E., Leinwand, L. A., et al. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.04.005 · Cited by 114
Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target
Lechner, S., Malgapo, M. I. P., Grätz, C., Steimbach, R. R., Baron, A., Rüther, P. L., Nadal, S., Stumpf, C., Loos, C., Ku, X., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01015-5 · Cited by 121
Selective HDAC1/HDAC2 Inhibitors Induce Neuroblastoma Differentiation
Frumm, S. M., Fan, Z. P., Ross, K. N., Duvall, J. R., Gupta, S., VerPlank, L., Suh, B., Holson, E. B., Wagner, F. F., Smith, W. B., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.03.020 · Cited by 114
Self-citationInvestigating the Sensitivity of NAD+-dependent Sirtuin Deacylation Activities to NADH
Madsen, A. S., Andersen, C. D., Daoud, M., Anderson, K. A., Laursen, J. S., Chakladar, S., Huynh, F. K., Colaço, A. R., Backos, D. S., Fristrup, P., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.668699 · Cited by 111
Epigenetic mechanisms of neuroplasticity and the implications for stroke recovery
Felling, R. J., & Song, H. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.09.017 · Cited by 114
Wu, R., Lu, Z., Cao, Z., & Zhang, Y. (2011) · Journal of the American Chemical Society · doi:10.1021/ja111104p · Cited by 108
Koppel, I., & Timmusk, T. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.015 · Cited by 108
Mechanisms of Resistance to Histone Deacetylase Inhibitors
Lee, J., Choy, M. L., & Marks, P. A. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394387-3.00002-1 · Cited by 110
Fass, D. M., Reis, S. A., Ghosh, B., Hennig, K. M., Joseph, N. F., Zhao, W., Nieland, T. J. F., Guan, J., Kuhnle, C. G., Tang, W., et al. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.043 · Cited by 111
Self-citationYap, T. A., & Workman, P. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134532 · Cited by 107
HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer
Stojanovic, N., Hassan, Z., Wirth, M., Wenzel, P., Beyer, M., Schäfer, C., Brand, P., Kroemer, A., Stauber, R. H., Schmid, R. M., et al. (2016) · Oncogene · doi:10.1038/onc.2016.344 · Cited by 109
Kerr, E. M., Holohan, C., McLaughlin, K. M., Majkut, J., Dolan, S., Redmond, K. M., Riley, J. S., McLaughlin, K. M., Stasik, I., Crudden, M. T. C. M., et al. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.8 · Cited by 106
Epigenetic Changes in Pediatric Solid Tumors: Promising New Targets
Lawlor, E. R., & Thiele, C. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1921 · Cited by 104
A Novel Class of Small Molecule Inhibitors of HDAC6
Inks, E. S., Josey, B. J., Jesinkey, S. R., & Chou, C. J. (2011) · ACS Chemical Biology · doi:10.1021/cb200134p · Cited by 105
HDAC-dependent ventricular remodeling
Xie, M., & Hill, J. A. (2013) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2012.12.006 · Cited by 102
Metadata
- Authors
- Bradner, J. E., West, N., Grachan, M. L., Greenberg, E. F., Haggarty, S. J., Warnow, T., & Mazitschek, R.
- Affiliations
- Broad Institute (US)
- Harvard University (US)
- The University of Texas at Austin (US)
- Corresponding author
- Bradner, James E
- Mazitschek, Ralph
- Venue
- Nature Chemical Biology
- Published
- 2010-02-07
- Volume
- 6
- Issue
- 3
- Pages
- 238-243
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- PMC
- PMC2822059
- OpenAlex
- W2083784041
- Semantic Scholar
- 68c4985bcae290a761e64065e7e4cfe062700c7f
- Cited by
- 720
- References
- 31
- Citations by year
- 2026: 18 · 2025: 25 · 2024: 27 · 2023: 28 · 2022: 37 · 2021: 50 · 2020: 41 · 2019: 34 · 2018: 39 · 2017: 42 · 2016: 61 · 2015: 64 · 2014: 53 · 2013: 67 · 2012: 62
- FWCI
- 27.21
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Wellcome Trust
- National Institutes of Health (n01co12400-79-0-22)
- Centers for Disease Control and Prevention (N01-C0-012400)
- National Institute on Drug Abuse (R01DA028301)
- National Cancer Institute (N01-CO-012400, K08CA128972, P01CA078048, T32CA079443)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- histone deacetylase, histone deacetylase inhibitors, isoform selectivity, class I HDACs, class II HDACs, class IIa HDACs, focused libraries, chemical probes, enzyme inhibition mechanism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
